Besides NSCLC, several previous studies showed that increased expression level of CXCL5 was an adverse prognosis biomarker in pancreatic cancer, hepatocellular carcinoma, and bladder cancer.38, 39, 40. Here, CXCL5 is linked to urinary bladder carcinoma.